导航补充和替代药物使用,药物坚持和痛风患者中的草药相互作用风险:印度尼西亚的一项多中心横截面研究
Dzulfiana Ashan1, Elly Wahyudin2, Dezső Csupor3
1Postgraduate Program, Faculty of Pharmacy, Hasanuddin University, Makassar, Indonesia.
Journal of complementary & integrative medicine
|December 5, 2025
概括
超过一半的痛风患者使用辅助和替代医学 (CAM),往往会影响药物坚持并构成草药相互作用的风险. 医疗保健提供者必须教育患者CAM安全性,并监测潜在的相互作用.
科学领域:
- 类风湿病学 类风湿病学
- 综合医学是一个整体医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 补充和替代医学 (CAM) 的使用在全球范围内不断增加,特别是在寻求安全,负担得起和可访问的治疗方法的痛风患者中.
- 关于CAM流行,相关因素及其对痛风管理的影响的数据有限,需要进一步调查.
研究的目的:
- 为了确定CAM在痛风患者中使用的流行率.
- 识别与CAM利用相关的预测因素.
- 评估CAM对药物坚持的影响,并确定潜在的草药相互作用.
主要方法:
- 一项涉及430名痛风患者的横截面研究在印度尼西亚马卡萨尔市进行.
- 数据是通过覆盖人口统计,CAM和传统医学使用,感知和药物坚持的问卷收集的.
- 使用UpToDate数据库评估了潜在的草药相互作用.
主要成果:
- 52.8%的痛风患者报告使用CAM,草药是最常见的.
- 康复疗法使用与以前的经验和社会影响有关 (p<0.001).
- CAM使用者表现出明显较差的药物坚持率 (8.4%与0.5%相比),并确定了四种潜在的草药相互作用.
结论:
- 在痛风患者中频繁使用CAM需要医疗保健提供者对安全性,疗效和相互作用的教育.
- 需要制定战略来解决与CAM相关的药物不服药问题.
- 使用CAM的痛风患者中草药相互作用的临床监测至关重要.
相关概念视频
01:15Drug Dosing: Geriatric Patients
212
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
212
01:28Drug Therapy
232
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
232
01:27Combined Effects of Drugs: Synergism
6.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.7K
01:30Combined Effects of Drugs: Antagonism
11.5K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.5K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
141
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
141